{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-083084","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2023-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.432409+00:00","generated_at":"2026-06-13T04:57:03.719238+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Hepion Pharmaceuticals enters $24M ATM equity offering with Cantor Fitzgerald","bullets":["ATM sales agreement with Cantor Fitzgerald allows Hepion to sell up to $24M of common stock at market prices.","Commission of 3.0% of gross proceeds paid to Cantor; Company provides customary indemnification.","Shares sold under existing effective shelf registration statement (File No. 333-254996).","No obligation to sell; offering terminates upon full issuance or termination of agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-083084","json":"https://secwatch.observer/filing/0001104659-23-083084.json","markdown":"https://secwatch.observer/filing/0001104659-23-083084.md","text":"https://secwatch.observer/filing/0001104659-23-083084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923083084/0001104659-23-083084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923083084/tm2321697d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:57:03.719238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8cb55b40fd0c3e2ebfe1ea1ae367b749199426a","claim":"Hepion Pharmaceuticals, Inc. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at up to $24,000,000 (effective 2023-07-21).","evidence_excerpt":"On July 21, 2023, Hepion Pharmaceuticals, Inc. (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. as sales agent (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $24,000,000 (the “Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923083084/0001104659-23-083084-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"up to $24,000,000"},{"label":"Effective","value":"2023-07-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}